OLMA

Olema Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

4.510

-0.13(-2.802%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.760

Open

4.6008

VWAP

4.64

Vol

201.84K

Mkt Cap

317.47M

Low

4.490

Amount

935.73K

EV/EBITDA(TTM)

Total Shares

55.93M

-75.23M

EV/OCF(TTM)

P/S(TTM)

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

5 Analyst Rating

426.61% Upside

Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 23.75 USD with a low forecast of 18.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

426.61% Upside

Current: 4.510

Low

18.00

Averages

23.75

High

28.00

426.61% Upside

Current: 4.510

Low

18.00

Averages

23.75

High

28.00

Oppenheimer

Matthew Biegler

Outperform

downgrade

$25 -> $22

2025-05-14

Reason

Oppenheimer

Matthew Biegler

Price Target

$25 -> $22

2025-05-14

downgrade

Outperform

Reason

Oppenheimer analyst Matthew Biegler lowered the firm's price target on Olema Oncology to $22 from $25 and keeps an Outperform rating on the shares following quarterly results. Arguably, their biggest catalyst is later this year with the potential for early OP-3136 Phase 1 data, the firm notes.

JP Morgan

Anupam Rama

Buy

Maintains

$30 → $28

2025-03-28

Reason

JP Morgan

Anupam Rama

Price Target

$30 → $28

2025-03-28

Maintains

Buy

Reason

JPMorgan lowered the firm's price target on Olema Oncology to $28 from $30 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotech group.

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$30

2025-03-19

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$30

2025-03-19

Reiterates

Strong Buy

Reason

Oppenheimer

Matthew Biegler

Buy

Reiterates

$30 → $25

2025-03-19

Reason

Oppenheimer

Matthew Biegler

Price Target

$30 → $25

2025-03-19

Reiterates

Buy

Reason

Oppenheimer analyst Matthew Biegler lowered the firm's price target on Olema Oncology to $25 from $30 but keeps an Outperform rating on the shares after its Q4 results. The negative sentiment for the oral SERD class has impacted Olema price of late, but with shares now trading under cash, investors get an opportunity to add to existing positions, the analyst tells investors in a research note. Investors have written off oral SERD developers completely after EMBER-3 and more recently VERITAC-2, but there is a big binary coming in the form of PersevERA, and if positive, it could resuscitate the modality and then some, the firm added.

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$30

2025-03-11

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$30

2025-03-11

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$30

2025-03-05

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$30

2025-03-05

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Olema Pharmaceuticals Inc (OLMA.O) is -2.44, compared to its 5-year average forward P/E of -7.05. For a more detailed relative valuation and DCF analysis to assess Olema Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.05

Current PE

-2.44

Overvalued PE

0.61

Undervalued PE

-14.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.85

Current EV/EBITDA

0.46

Overvalued EV/EBITDA

3.21

Undervalued EV/EBITDA

-10.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00